reports
Outlook Therapeutics® to Present at the Retina World Congress 2024
Outlook Therapeutics® to Present at the Retina World Congress 2024 ISELIN, N.J., May 02, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the being held May 9-12, 2024 in Fort Lauderdale, FL. Details for the presentations are as follows: Session: Retina UnpluggedPanelist: Russell Trenary, President and Chief Executive OfficerDate and Time: Thursday, May 9, 2024...
- Jonathan Moreland
FFIN FIRST FINANCIAL BANKSHARES INC
CINF CINCINNATI FINANCIAL CORPORATION
CHDN CHURCHILL DOWNS INCORPORATED
HWBK HAWTHORN BANCSHARES
NQP NUVEEN PENNSYLVANIA INVESTMENT QUALITY MUNICIPAL FUND INC.
NXJ NUVEEN NEW JERSEY DIVIDEND ADVANTAGE MUNICIPAL FUND
CLF CLIFFS NATURAL RESOURCES INC.
PWOD PENNS WOODS BANCORP INC.
PCB PACIFIC CITY FINANCIAL CORP
RYES PATRIOT MINEFINDERS INC.
HQL TEKLA LIFE SCIENCES INVESTORS
BHRB BURKE & HERBERT BANK & TR/VA
NPCT NUVEEN CORE PLUS IMPACT FD
GNLX GENELUX CORP
LSXMK LIBERTY SIRIUSXM GROUP
NBBK NB BANCORP INC.
ASGI ABERDEEN STANDARD GLOBAL INFRASTRUCTURE INCOME FUND
Westwood Holdings Group, Inc. Reports First Quarter 2024 Results
Westwood Holdings Group, Inc. Reports First Quarter 2024 Results Strong Performance across Westwood's suite of products Successful Launch of MDST on the NYSE (April, 2024) Successful Launch of WEEI on NASDAQ (May, 2024) DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- Westwood Holdings Group, Inc. (NYSE: WHG) today reported first quarter 2024 earnings. Significant items included: SMidCap, SmallCap Value, MidCap Value, Platinum, Enhanced Balanced, High Income, Credit Opportunities and Global Real Estate strategies all beat their primary benchmarks.SmidCap and Enhanced Balanced posted top quart...
Westwood Announces Launch of Westwood Salient Enhanced Energy Income E...
Westwood Announces Launch of Westwood Salient Enhanced Energy Income ETF (WEEI) Westwood’s Second ETF Rounds Out High-Yielding Investment Offerings for the Energy Sector DALLAS, May 01, 2024 (GLOBE NEWSWIRE) -- (WHG), a publicly-traded investment management boutique and wealth management firm, today launched the Westwood Salient Enhanced Energy Income ETF (NASDAQ: WEEI), the second . Like its sister product, the Westwood Salient Enhanced Midstream Income ETF (NYSE: MDST), WEEI is an actively managed ETF crafted to provide advisors and investors with a robust solution for generating hig...
Olema Oncology to Participate in Upcoming Investor Conferences in May
Olema Oncology to Participate in Upcoming Investor Conferences in May SAN FRANCISCO, May 01, 2024 (GLOBE NEWSWIRE) -- (“Olema”, “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for women’s cancers, today announced that its management team will participate in the following upcoming investor conferences: BofA Securities Health Care Conference 2024Date: Tuesday, May 14, 2024, at 4:35 p.m. PTLocation: Encore Hotel in Las Vegas, NVFormat: Presentation H.C. Wainwright 2nd Annual BioC...
Euronet Worldwide Reports First Quarter 2024 Financial Results
Euronet Worldwide Reports First Quarter 2024 Financial Results LEAWOOD, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Euronet Worldwide, Inc. (“Euronet” or the “Company”) (NASDAQ: EEFT), a leading global financial technology solutions and payments provider, reports first quarter 2024 financial results. Euronet reports the following consolidated results for the first quarter 2024 compared with the same period of 2023: Revenues of $857.0 million, a 9% increase from $787.2 million (9% increase on a constant currency1 basis).Operating income of $64.0 million, a 40% increase from $45.6 million (4...
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summi...
Outlook Therapeutics® to Present at the Ophthalmology Innovation Summit (OIS) Retina Innovation Showcase ISELIN, N.J., April 29, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve the first approval for an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and the EU, today announced it will present at the being held May 4, 2024 in Seattle, WA. Details for the presentations are as follows: Innovation Showcase: Company PresentationRussell Trenary, President and Chief Executive OfficerSatur...
Sight Sciences Announces Successful $34 Million Patent Infringement Ve...
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery MENLO PARK, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it received a positive jury trial verdict of $34 million associated with the patent infringement case it filed on September 16, 2021 against Alcon Inc., Alcon Vision...
- David Carlson
- David Nierengarten
- Dennis Pak
- Laura Chico
- Martin Fan
- Ritika Das
- Robert Driscoll
- Sam Ravina
RARE ULTRAGENYX PHARMACEUTICAL INC.
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
ARDX ARDELYX INC
UTHR UNITED THERAPEUTICS CORPORATION
GTHX G1 THERAPEUTICS
SWTX SPRINGWORKS THERAPEUTICS
Home BancShares, Inc. Announces Second Quarter Cash Dividend
Home BancShares, Inc. Announces Second Quarter Cash Dividend CONWAY, Ark., April 24, 2024 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB), parent company of Centennial Bank, today announced that its Board of Directors has declared a regular $0.18 per share quarterly cash dividend payable June 5, 2024, to shareholders of record May 15, 2024. This cash dividend is consistent with the quarterly dividends paid during 2023. Home BancShares, Inc. is a bank holding company, headquartered in Conway, Arkansas. Its wholly-owned subsidiary, Centennial Bank, provides a broad range of commerci...
Bankwell Financial Group Reports Operating Results for the First Quart...
NEW CANAAN, Conn.--(BUSINESS WIRE)-- Bankwell Financial Group, Inc. (NASDAQ: BWFG) reported GAAP net income of $3.8 million, or $0.48 per share for the first quarter of 2024, versus $10.4 million, or $1.33 per share, for the same period in 2023. Pre-tax, pre-provision net revenue ("PPNR") was $8.8 million, or $1.14 per share, for the first quarter of 2024, versus $14.4 million, or $1.89 per share for the same period in 2023. The Company's Board of Directors declared a $0.20 per share cash dividend, payable May 21, 2024 to shareholders of record on May 10, 2024. We recommend reading this ea...
Quest Resource Holding Corporation Announces Continued Strong Business...
Quest Resource Holding Corporation Announces Continued Strong Business Momentum and First Quarter 2024 Earnings and Conference Call Date Additional Significant Client Win to Start Off the Second Quarter Financial Results and Earnings Conference Call to be held at 5pm ET on Thursday, May 9, 2024 THE COLONY, Texas, April 24, 2024 (GLOBE NEWSWIRE) -- Quest Resource Holding Corporation ( ("Quest" or the “Company”), a national leader in environmental waste and recycling services, today announced continued strong business momentum and details of its first quarter 2024 earnings release date an...
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offe...
Centessa Pharmaceuticals Announces Pricing of $100 Million Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced the pricing of an underwritten public offering of 10,810,810 American Depositary Shares (“ADSs”), each representing one ordinary share, at a price to the public of $9.25 per ADS. The aggregate gross proceeds to Centessa from this offering are expected to be approximately $100 mi...
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offeri...
Centessa Pharmaceuticals Announces $100 Million Proposed Public Offering of American Depositary Shares BOSTON and LONDON, April 23, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that it has commenced an underwritten public offering of $100 million of American Depositary Shares (“ADSs”), each representing one ordinary share. All of the ADSs are being offered by Centessa. In addition, Centessa intends to grant the underwriters a 30-day option to purchase up...
CRISPR Therapeutics to Present Oral Presentation at the American Socie...
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting ZUG, Switzerland and BOSTON, April 22, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced an oral presentation highlighting the Company's lipid nanoparticle (LNP) approach for ocular editing will be presented at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Meeting, taking place May 7 – 11, 2024, in Baltimore, MD and vi...
CrossAmerica Partners LP Maintains Quarterly Distribution
CrossAmerica Partners LP Maintains Quarterly Distribution Allentown, PA, April 22, 2024 (GLOBE NEWSWIRE) -- CrossAmerica Partners LP Maintains Quarterly Distribution Quarterly distribution of $0.5250 per unit attributable to the first quarter of 2024 ALLENTOWN, PA (April 22, 2024) – CrossAmerica Partners LP (NYSE: CAPL) announced today that the Board of Directors of its general partner has approved a quarterly distribution of $0.5250 per unit attributable to the first quarter of 2024 (annualized $2.10 per unit). The distribution attributable to the first quarter is payable on May 10, ...
Euronet and SOFTONE Group Announce Agreement to Provide Integrated Mer...
Euronet and SOFTONE Group Announce Agreement to Provide Integrated Merchant Acquiring Services in Greece A comprehensive offering will be available to the companies’ combined customer base of more than 285,000 merchants as well as the broader Greek market LEAWOOD, Kan., April 22, 2024 (GLOBE NEWSWIRE) -- Euronet (NASDAQ: EEFT), a leading global financial technology solutions and payments provider, and SOFTONE Group, one of the largest cloud-based business software providers in Greece and Southeast Europe, announced today that they are partnering to deliver integrated merchant acquiring ...
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Conce...
Centessa Pharmaceuticals Announces Open IND for ORX750; Proof-of-Concept Data in Sleep-Deprived Healthy Volunteers Planned for 2H 2024 BOSTON and LONDON, April 22, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: CNTA), a clinical-stage pharmaceutical company that aims to discover and develop medicines that are transformational for patients, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug application (IND) to initiate a Phase 1 first-in-human, clinical trial of ORX750 for the treatment of narcolepsy. ORX750 is an investigational, orally administ...
Sight Sciences to Report First Quarter Financial Results on May 2, 202...
Sight Sciences to Report First Quarter Financial Results on May 2, 2024 MENLO PARK, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the first quarter ended March 31, 2024, after the market close on Thursday, May 2, 2024. The Company’s management will discuss the results during a conference call beginning at 1:30 p.m. Pacific ...
All Operating Metrics Up and Expenses Down, Great Start at HOMB
All Operating Metrics Up and Expenses Down, Great Start at HOMB CONWAY, Ark., April 18, 2024 (GLOBE NEWSWIRE) -- Home BancShares, Inc. (NYSE: HOMB) (“Home” or the “Company”), parent company of Centennial Bank, released quarterly earnings today. Quarterly Highlights MetricQ1 2024Q4 2023Q3 2023Q2 2023Q1 2023Net income$100.1 million$86.2 million$98.5 million$105.3 million$103.0 millionNet income, as adjusted (non-GAAP)(1)$99.2 million$92.2 million$94.7 million$102.6 million$108.9 millionTotal revenue (net)$246.4 million$245.6 million$245.4 million$257.2 million$248.8 millionIncome before in...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.